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Abstract
Anxiety and depression are associated with increased pain responses in chronic pain states. The extent to which anxiety drives
chronic pain, or vice versa, remains an important question that has implications for analgesic treatment strategies. Here, the effect of
existing anxiety on future osteoarthritis (OA) pain was investigated, and potential mechanisms were studied in an animal model.
Pressure pain detection thresholds, anxiety, and depression were assessed in people with (n 5 130) or without (n 5 100) painful
knee OA. Separately, knee pain and anxiety scores were also measured twice over 12months in 4730 individuals recruited from the
general population. A preclinical investigation of a model of OA pain in normo-anxiety Sprague-Dawley (SD) and high-anxiety Wistar
Kyoto (WKY) rats assessed underlying neurobiological mechanisms. Higher anxiety, independently from depression, was
associated with significantly lower pressure pain detection thresholds at sites local to (P , 0.01) and distant from (P , 0.05) the
painful knee in patients with OA. Separately, high anxiety scores predicted increased risk of knee pain onset in 3274 originally pain-
free people over the 1-year period (odds ratio 5 1.71; 95% confidence interval 5 1.25-2.34, P , 0.00083). Similarly, WKY rats
developed significantly lower ipsilateral and contralateral hind paw withdrawal thresholds in the monosodium iodoacetate model of
OA pain, compared with SD rats (P 5 0.0005). Linear regressions revealed that baseline anxiety-like behaviour was predictive of
lowered paw withdrawal thresholds in WKY rats, mirroring the human data. This augmented pain phenotype was significantly
associated with increased glial fibrillary acidic protein immunofluorescence in pain-associated brain regions, identifying supraspinal
astrocyte activation as a significant mechanism underlying anxiety-augmented pain behaviour.
1. Introduction
Chronic pain remains a global clinical problem. Negative affect,
including anxiety and depression, is associated with lower pain
thresholds in healthy individuals52 and is exacerbated in chronic
pain states,13 including musculoskeletal disorders such as low
back pain.7,53 Negative affect is also common in people with
osteoarthritis (OA),3 the most prevalent joint disease and a major
cause of disability and chronic musculoskeletal pain.14 Both
anxiety and depression have direct effects on reported current
OA pain, and pain reported the followingweek.45Whether anxiety
predicts long-term worsening of OA pain, facilitation of pain, and/
or a spread of pain to remote nondiseased areas2,37,59 remains
unknown. The association of negative affect with greater use of
opioid analgesics5,38,54 and worse treatment outcomes to
arthroplasty1,35,56 warrants further investigation of the impact of
negative effect on OA pain.
Multiple brain regions have fundamental roles in the processing
of negative affect and chronic pain. Among these, the periaque-
ductal gray (PAG) and anterior cingulate cortex (ACC) have well-
documented roles in anxiety,12,31 and both regions are activated
in people with OA pain.4,19 Human imaging studies revealed ACC
activation during anticipation of pain, which was correlated with
the level of anxiety–pain interactions.58 The PAG, a major
component of a descending pain system, normally provides
tonic inhibition of spinal cord nociceptive responses.29 Imaging
studies in OA subjects revealed differences in activity in brainstem
regions including the PAG, which were related to pain pressure
thresholds,19 and neural correlates of reported OA pain intensity
mapped to limbic affective circuits were explained by trait
anxiety.11
We hypothesised that higher anxiety scores are associated
with high OA pain scores and spread of pain to nondiseased
areas. To test this, quantitative sensory testing (QST) was used to
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measure pressure pain detection thresholds (PPTs), alongside
anxiety and depression scores in people with or without painful
knee OA. Whether preexisting anxiety contributed to future knee
pain severity was also evaluated using questionnaire data from
a community cohort at 2 time points.
The disconnect between the preclinical efficacy of candidate
treatments and success in the clinic is frequently attributed to
a preclinical focus on sensory pain, which fails to account for the
contribution of affective responses.9 Thus, the second part of this
study back-translated our clinical findings to investigate the
underlying neurobiological mechanisms in a rodent model of
negative affect. Wistar Kyoto (WKY) rats exhibit heightened
anxiety/depression, increased stress-induced behavioural
responses,8 and hypothalamic–pituitary–adrenal axis activa-
tion.46 Rat models of OA pain mimic key histopathological
features of human OA,55 and exhibit spinal neuronal hyperexcit-
ability43 and glial cell activation.42,60 Using the WKY strain of rats
to model comorbid negative affect and OA pain, we investigated
the potential contribution of astrocytes (using glial fibrillary acidic
protein [GFAP] immunofluorescence) at spinal and supraspinal
sites to altered OA pain responses. Our novel findings have
important implications for the identification of novel targets for
treatments and the use of antianxiety medications as analgesic
adjuvants in OA pain.
2. Methods
2.1. Clinical subjects
Participants from a community-based cohort study aged 40
years and older (“Knee Pain and Related Health in the
Community” study)16 were recruited by post through general
practice registers in the East Midlands. This study was approved
by the Nottingham Research Ethics Committee 1 (NREC Ref: 14/
EM/0015) and registered (clinicaltrials.gov portal: NCT02098070)
in line with the Declaration of Helsinki. Participants provided
written informed consent and completed a questionnaire evalu-
ation including the Hospital Anxiety and Depression Scale
(HADS), which has been validated against a structured clinical
interview by a liaison psychiatrist of depression or anxiety in
people with OA,3 and a knee pain questionnaire. A subset of
participants were invited to undergo a hospital-based assess-
ment involving knee radiographs and PPTs on both knees and the
sternum.
Associations between knee pain, anxiety, and depression
scores were tested using questionnaire data from 4730
community-recruited individuals, of whom 3274 participants
without knee pain at baseline also underwent a 12-month follow-
up. A subgroup of 230 participants were selected for PPT
assessments—130 individuals with current knee pain (present
most days, lasting more than 3 months) and radiographic knee
OA (Kellgren–Lawrence [KL] radiographic score .2 in the
tibiofemoral [TF] or patellofemoral [PF] compartments of either
knee), plus 100 knee pain–free individuals without radiographic
knee OA.
2.2. Pressure pain detection thresholds
Quantitative sensory testing for PPTs was performed on
individuals using an electronic pressure algometer connected to
a laptop and a patient switch (Somedic Sensebox; Somedic
SenseLabs, So¨sdala, Sweden). Quantitative sensory testing was
conducted at the medial TF joint line of the most painful knee, or
the right knee if there was no pain in either, and also at sites distal
to (anterior tibia) and distant from (sternum) the index knee.
Pressure pain detection threshold assessment has been
standardized by ourselves, and others, at these sites in people
with OA47,51.
Participants were first familiarized with the procedure by
applying the stimulus to a learning site on one hand. Pressure
pain detection thresholds were then measured sequentially at
sternum, medial knee, and anterior tibia. For each test, the
pressure (kPa) was recorded at which pain was first experienced
during application of progressively increasing pressure using
a probe with a 1 cm2 blunt end and a constant ramp of 50 kPa per
second.37 The test stimulus was applied to each site 3 times.
The intraclass correlation coefficient for 2 raters was calculated
taking the log of the pressure pain thresholds measured in 9
independent subjects. The intraclass correlation coefficients
(95%confidence intervals [CIs]) obtainedwere as follows: anterior
tibia 0.69 (0.32-0.87), knee lateral 0.85 (0.63-0.94), knee medial
0.81 (0.56-92), and sternum 0.64 (0.26-0.85). The medial,
anterior tibia, and lateral PPTs refer to the index knee, which
was a knee at random for controls, the only painful knee for
individuals with unilateral knee pain, and themost painful knee for
individuals with bilateral knee OA, respectively.
2.3. Radiographic evaluation
Tibiofemoral andPF radiographswere taken using a standardised
protocol [standing posterior–anterior and skyline views] and
scored by experienced observers with intrarater and interrater
reliability tests performed. A Perspex Rosenberg template with
lead beads was used for the standing posterior–anterior view to
standardise the degree of knee flexion, foot rotation, and
magnification.41 Posterior–anterior radiographs were taken with
the patient facing the x-ray tube while standing on the Rosenberg
jig and leaning forwards with their thighs touching the anterior
aspect of the jig, the x-ray beams passing from the posterior
aspect through to the anterior aspect of the knee. Variable jigs
were used for the skyline view to obtain 30˚ of knee flexionwith the
participant lying in a reclined supine position on a couch. Grading
of radiographs for changes of OA included the summated KL
score and the Nottingham logically devised line drawing atlas for
individual scoring of osteophyte (0-5) and joint space width (21 to
15) for each medial TF, lateral TF, and PF compartment.
Individuals were classified as OA positive if they had a KL grade
$2 at either compartment in one or both knees, based on the
above definition.
2.4. Questionnaire evaluation
The HADS is a self-screening, 14-item questionnaire incorporat-
ing anxiety and depression subscales, which is extensively used
in primary care.3 The anxiety and depression subscales can each
take values ranging from 0 to 21 and scores are categorised as
normal (0-7), mild (8-10), moderate (11-14), and severe (15-21).
For the current study, we used the standard cutoff of #10
between normal/mild for low anxiety or depression and .10 for
moderate or severe.62
The Intermittent and Constant Osteoarthritis Pain (ICOAP)
scale is an 11-item questionnaire, divided into 2 domains: a first
5-item scale for constant pain and a 6-item scale for intermittent
pain (so-called “pain that comes and goes”). Each domain
captures pain intensity as well as related distress and the impact
of OA pain on quality of life. Preliminary data suggested the new
measure to be valid and reliable.20 For the current analysis, we
only used the pain intensity of the constant and intermittent pain
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domains. A 0 to 10 numerical rating scale (NRS) was used for self-
assessment of pain intensity in the past month.
2.5. Statistical analysis
Questionnaire data outcomes were: HADS anxiety score .10 at
12 months in individuals with baseline anxiety scores ,9 and
presence of knee pain.15 days of the month and lasting at least
3 months in individuals with no knee pain at baseline. Pressure
pain detection threshold values for sternum, knee medial, knee
lateral, and anterior tibia are expressed in log10 kPa. Additional
outcomes were pain intensity measures for constant and
intermittent pain (0-5) and a 0 to 10 NRS to assess pain intensity
in the past month. Associations between pain outcomes and
HADS anxiety and depression status were tested using standard
linear regressions. Correlations between anxiety and depression
HADS scores and other quantitative variables were determined
using Spearman correlation coefficient. Age, sex, and body mass
indexwere included as covariates in all analyses. Other covariates
included are specifically mentioned in the text. Association is
expressed as the linear regression coefficient beta and the
corresponding 95% CIs; P , 0.05 was considered statistically
significant. Analyses were performed in R (version 3.1.2; the R
Foundation for Statistical Computing, Vienna, Austria). The study
was powered to detect with 80% power, and P , 0.05
differences of 0.57 StDev in knee OA and of 0.93 StDev in
controls between high vs low anxiety scores. These values
correspond to 0.16 and 0.21 log kPa in knee OA and controls,
respectively. Because the effect size for PPTs in healthy controls
is about half that seen in OA cases, this impacts on the power to
detect a statistically significant (,40%) difference in the control
group.
2.6. Preclinical model of osteoarthritis pain and anxiety
Studies were in accordance with UK Home Office Animals
(Scientific Procedures) Act (1986) and ARRIVE guidelines.27
Ninety-one male rats were used: Sprague-Dawley (SD) n 5 16,
Wistar n 5 17 (Charles River, Margate, United Kingdom), Wistar
Kyoto (WKY) n 5 57 (Envigo, Bicester, United Kingdom). Rats
were housed in groups of 3 to 4 on a 12-hour light–dark cycle in
a specific pathogen-free environment with ad libitum access to
standard rat chow and water. Rats were randomly assigned to
groups, and experimenters were blinded to all treatments. Males
were used to reduce variability, and thus the number of animals
required, andmaintain consistency with previouswork character-
ising the monosodium iodoacetate (MIA) model in SD rats. When
comparing more detailed longitudinal changes in anxiety-like
behaviour in WKY rats, Wistar rats were used as the most
genetically similar control strain.
2.7. Osteoarthritis model and behavioural assessments
Unilateral intra-articular injection of (MIA) was used to model OA
pain in adult male SD andWKY rats (MIA n5 10; saline n5 6 per
strain). Rats were anesthetised (isoflurane 2.5%-3% in 1 L/
minutes O2) and received a single intra-articular injection of 1 mg
of MIA (Sigma, United Kingdom) in 50 mL saline, or saline alone,
through the infrapatellar ligament of the left knee.43 Group
allocations were randomised by an independent investigator. The
MIA model was chosen over surgical models to minimise the
impact of surgical pain not related to OA in this study. The MIA
model mimics key elements of joint pathology and clinical OA pain
(see references in Ref. 6).
Weight-bearing asymmetry was measured with an incapaci-
tance tester (Linton Instrumentation, Diss, United Kingdom). Paw
withdrawal thresholds (PWTs) were determined for each hind
paw using the up-down method as previously described.42
Briefly, von Frey hairs (vFH; Semmes-Weinstein; bending forces
0.4-26 g) were applied to the plantar surface of the hind paw for 3
seconds and the presence or absence of a withdrawal response
was recorded. Pain behaviour was assessed at baseline, and
then 2 to 3 times per week until 28 days after MIA or saline
injection. Joint pathology was assessed at the end of experi-
ments, as previously described.33 Tibiofemoral joints were
removed, postfixed in neutral buffered formalin (10%), decalcified
in EDTA, then processed, and stained with haematoxylin and
eosin, to enable scoring of joint pathology. Cartilage surface
integrity was scored from 0 (healthy) to 5 (full-thickness de-
generation), and a total joint damage score (range 0-15) was
calculated as cartilage surface integrity score (0-5) 3 proportion
of damaged cartilage (0-3). Inflammation was graded on a scale
from 0 (lining cell layer 1-2 cells thick) to 3 (lining cell layer.9 cells
thick and/or severe increase in cellularity).
Anxiety-like behaviour was determined via time in the central
zone of an open-field arena for comparisons between SD and
WKY rats. Sprague-Dawley andWKY ratswere placed in a corner
of an open-field testing arena, comprising an opaque white
plastic box (60 cm 3 63 cm, wall height 20 cm). Behaviour was
then assessed for a period of 5 minutes, with total duration in the
central zone (20 cm3 20 cm), frequency of entries to the central
zone, and total distance moved quantified using EthoVision
software (Noldus Information Technology; the Netherlands25) or
manual scoring. More detailed examination of the association
between pain and anxiety-like behaviour in Wistar and WKY rats
was assessed via area under the curve (AUC) for time spent in the
open arm in the elevated plus maze (EPM) at baseline and 18 to
21 days after intra-articular injection of saline (Wistar: n5 6,WKY:
n 5 8) or MIA (Wistar: n 5 11, WKY: n 5 7). To control for any
strain differences in locomotor activity, total distance travelled
was assessed in the EPM and via the number of beam breaks in
locomotor activity boxes. To prevent habituation to the testing
equipment, the maze was rotated 90˚ and visual cues in the room
altered for the second measurement. Anxiety status was
determined by comparing individual AUC values to the mean
AUC value for all animals at each time point. Individual animals
with AUC values below the mean value were considered anxious
and those with values above the mean value were considered
nonanxious. These data were used for linear regression analyses.
2.8. Immunohistochemical analysis of glial cell activation
Perfusion-fixed spinal cord and brain tissue were collected and
glial cell activation was analysed as previously described42 in
lumbar dorsal horn of the spinal cord, PAG, and ACC.
Briefly, 40-mm spinal cord sections were immunolabelled with
primary antibodies against ionized calcium binding adapter
molecule (IBA1; rabbit, 1:1000, Wako, Neuss, Germany) for
microglia, and GFAP (mouse, 1:100; Fisher Scientific, Lough-
borough, United Kingdom) for astrocytes. Activated microglia
with pronounced swelling of the soma and reduced ramified
process numberwere considered activated, and the total number
of these cells expressing IBA1 (goat 1:100; Abcam, Cambridge,
United Kingdom, ab5076) and phosphorylated-p38 (P-p38; 1:
300, Cell Signalling, 9211) and P-p38 were counted (n 5 5
sections/animal, n 5 5 animals/group). In brain, 20-mm sagittal
cryosections containing PAG and ACC were immunolabelled for
GFAP (rabbit, 1:100; DAKO, Cambridge, United Kingdom).
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Primary antibodies were detected with Alexa Fluor 488 goat anti-
rabbit (IBA-1, P-p38) or Alexa Fluor 568 goat anti-mouse (GFAP),
all at 1:300 (Molecular Probes, Eugene, OR), and sections were
imaged using a 20 3 0.4 NA objective lens on a Leica DMIRE2
fluorescence microscope. For GFAP figures, additional repre-
sentative high-quality images of GFAP labelling for each brain
region were obtained using a Zeiss LSM880C confocal micro-
scope (20 3 0.5 NA objective). Briefly, a z-stack of 12 images
collected at 0.5-mm intervals was obtained from one section per
animal, with identical acquisition settings, andmaximum-intensity
projections were generated using ImageJ.
2.9. Quantification of glial cell activation
Microglia were morphologically assessed for activation status by
an experimenter blinded to the treatment. IBA-1–positive cells
were considered activated if they displayed pronounced swelling
of the cell body and significantly reduced ramified process
number. The total number of contralateral dorsal horn–activated
microglia was subtracted from the ipsilateral total to give
a measure of MIA-induced change in microglial activation.
Similarly, for P-p38, the total number of DAPI-positive cells
expressing P-p38 was manually counted.
For GFAP immunofluorescence, number of pixels with mean
gray intensity.45 was determined for each region using Volocity
5.5 software.
2.10. Duloxetine intervention
To probe mechanisms linking OA pain behaviour, negative affect,
and brain glial cell responses, effects of the serotonin and
noradrenaline reuptake inhibitor (SNRI) duloxetine were studied.
Duloxetine is an effective analgesic in 30% to 50%of patients with
OA knee pain,57 a similar proportion to the 40% demonstrating
symptoms of negative affect.3 These data suggest that treat-
ments targeting the interaction between negative affect and pain
may have greater utility in this subpopulation of OA sufferers.
WKY rats were injected with MIA (n5 20) and randomly stratified
into drug or vehicle treatment at day 14. At day 20, duloxetine (30
mg/kg, subcutaneous, n5 10) or vehicle (1% ethanol, 1% Tween
80 in saline, n5 10) was injected once daily for 3 days, and pain
behaviour was compared to WKY/saline rats treated with vehicle
(n5 6). On day 22, pain behaviour was assessed 2.5 hours after
treatment, tissue collected, and GFAP expression analysed. The
dose of duloxetine was based on previous evidence of analgesic
efficacy in rodent models of pain.23,50
2.11. Statistical analyses
Data were analysed using Prism 5.0 software (GraphPad, La
Jolla, CA) with 1-way or 2-way analysis of variance tests with
Bonferroni post hoc testing, or unpaired two-tailed t tests, as
appropriate, and are reported as mean 6 SEM (parametric
data), or median 6 interquartile range (nonparametric data). P
, 0.05 was considered statistically significant. Associations
between pain and anxiety scores were assessed via standard
linear regression models using binary thresholds for pain and
anxiety. Ipsilateral pain was defined as a change of $23 vFH
PWT from baseline; contralateral pain as$22 vFH difference;
and anxiety as open arm AUC , mean of all animals.
Immunofluorescence data were analysed using nonparamet-
ric Kruskal–Wallis tests with Dunn post hoc testing.
Correlations between GFAP intensity and pain behaviour were
determined using Spearman correlation.
3. Results
3.1. Clinical data
3.1.1. Anxiety and depression: higher pain scores and lower
pain pressure thresholds in people with knee OA
The clinical and demographic characteristics of study partic-
ipants are presented in Table 1. Pressure pain detection
thresholds at each of the 4 sites were lower in the OA cohort
than in the pain-free cohort (Table 1). Hospital Anxiety and
Depression Scale anxiety scores were correlated with depression
scores in the whole sample (Spearman’s R5 0.58, P, 0.0001).
Anxiety and depression scores were significantly higher in the OA
cohort, with moderate or high anxiety reported in 25%, and
depression in 10%, of OA cases (HADS scores .10) (Table 1).
Scores were strongly correlated with self-reported pain and PPTs
before any adjustments (data not shown), and remained
significantly correlated after adjustment for covariates (Table
S1, available at http://links.lww.com/PAIN/A696).
Hospital Anxiety and Depression Scale anxiety and depression
scores are not normally distributed; so, individuals were stratified
into severe/moderate vs mild/normal anxiety and depression
categories using previously validated cutoffs3,21 analysing cases
and controls separately, and adjusting for covariates. The
magnitude of pain scores for these groups is shown graphically
in Figure 1. In individuals with painful kneeOA, anxiety status was
significantly associated with all 3 of the self-reported pain
measures (Table 2 and Fig. 1A) and with PPTs at the medial
and lateral knee, anterior tibia, and sternum (Table 2 and Figs.
1B–E). The coefficients for the association between anxiety and
PPTs, and anxiety and self-reported pain in the knee OA cohort
remained significant after adjustment for depression (Table 2).
However, after adjustment for anxiety status, depression only
remained associated with NRS pain intensity (Table 2). Neither
anxiety nor depression status was significantly associated with
PPTs in the pain-free cohort (Table 2 and Fig. 1).
To investigate the potential temporal link between pain and
anxiety, we used questionnaire data at 2 time points from 4730
individuals from the community. The effect of a HADS anxiety
score .10 on the incidence of knee pain after 12 months was
studied. Data from 3274 individuals who reported that they did
not have knee pain at baseline (of whom 351 had a HADS anxiety
score.10) were entered into a logistic regression model with the
outcome being pain at 12 months (defined as presence of knee
pain .15 days of the month and lasting at least 3 months). This
analysis yielded an odds ratio (OR) of 1.96 (95%CI 1.46-2.61;P,
0.0000054). We further adjusted for the presence of depression
asmeasured by HADS. This resulted in a slightly lower OR5 1.71
(95% CI 1.25-2.34 P , 0.00083). The effect of depression on
knee pain onset, adjusted for anxiety, was OR 5 1.66 (95% CI
1.09-2.53; P , 0.018).
A similar analysis was performed to investigate whether knee
pain predicts the onset of anxiety 12 months later. Data from
3767 individuals with a baseline HADS anxiety score .10 were
analysed, of which 1020 reported baseline knee pain. A logistic
regression model including age, sex, and body mass index as
covariates used baseline knee pain (15 days or more for the past
month) as the predictor variable. This yielded an OR5 1.91 (95%
CI 1.35-2.70 P , 0.010), which lowered to OR 5 1.18 (95% CI
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0.79-1.77 P, 0.40) when adjusted for baseline depression status.
Assessing the effect of depression at baseline on theonset of anxiety
(HADS. 10) 12months later yieldedOR5 3.20 (95%CI 1.69-6.09;
P , 0.0004). These data demonstrate that both anxiety and
depression at baseline are associated with increased risk of knee
pain at follow-up. By contrast, knee pain at baseline was not
significantly associated with onset of anxiety 12 months later.
3.2. Preclinical data
3.2.1. Altered pain phenotype in a rodent model of high
anxiety
To better understand the link between anxiety and knee pain, we
established a model of OA pain in a rat strain with elevated
baseline anxiety-like behaviour. Before model induction, WKY
rats display increased anxiety behaviour in the open-field test
(Figure S1, available at http://links.lww.com/PAIN/A696), but no
significant differences in PWTs compared with normo-anxiety SD
rats (Table S2, available at http://links.lww.com/PAIN/A696).
After intra-articular injection of MIA to model OA pain, weight-
bearing asymmetry (a measure of pain on loading) increased in
both strains of rats. However, WKY rats showed significantly
greater MIA-induced reductions in ipsilateral PWTs than SD rats,
and also displayed a contralateral phenotype not observed in the
SD strain, with significantly reduced contralateral PWTs from day
10 (Fig. 2A). Lowered PWTs are generally associated with the
presence of spinal sensitization mechanisms.32 Monosodium
iodoacetate–induced joint pathology was comparable between
WKY and SD rats at day 28 (Fig. 2B), supporting a role of central
mechanisms in mediating differences in pain responses.
Consistent with our clinical data, baseline scores of anxiety-like
behaviour in the EPM predicted the MIA-induced change in
contralateral PWTs (increased pain behaviour) in WKY rats
(Table 3), mimicking key aspects of our clinical data and
supporting the use of the WKY-MIA model to study the
mechanisms by which anxiety may influence OA pain.
3.3. Increased spinal and supraspinal glial cell responses
Given the well-established contribution of neuroimmune cells to
central sensitization and the transition to chronic pain,weprobed the
role of glial cell activation in pain-associated CNS regions. Astrocyte
andmicroglialmarkerswere assessed in thedorsal horn of the spinal
cord (Fig. 3) and brains (Fig. 4) from WKY and SD rats. A low-
magnification image of GFAP labelling in the spinal cord dorsal horn
and regions used for quantification can be found in the supplemen-
tary material (Figures S2 & S3, available at http://links.lww.com/
PAIN/A696). Quantification of GFAP immunofluorescence, amarker
of astrocytes, revealed higher levels bilaterally in the dorsal horn of
the spinal cord in saline-treatedWKY rats (WKY-sal), comparedwith
their SD counterparts (SD-sal, Figs. 3A and C). Importantly,
ipsilateral dorsal horn GFAP immunofluorescence was increased
to a significantly greater extent inWKY-MIA rats at 28 days (Figs. 3B
and C). No changes in GFAP were observed in the contralateral
dorsal horn of WKY-MIA rats, compared to WKY-sal (Fig. 3C).
However, lowered contralateral PWTs were correlated with GFAP
immunofluorescence in the ipsilateral dorsal horn in WKY-MIA rats
(Spearman’s R 520.78, P5 0.0019, Fig. 3D).
By contrast, we observed no significant differences in MIA-
induced microglial activation between the 2 strains (Figs. 3E–G).
An increase in microglial activation was observed in the ipsilateral
spinal cord of both strains (Fig. 3G and S4, available at http://
links.lww.com/PAIN/A696), with a bilateral increase in P-p381
Table 1
Demographic and clinical characteristics of study
participants.
Controls Knee OA P
n 5 100 n 5 130
Mean StDev Mean StDev
Demographics
Age 60.27 9.61 63.06 8.88 0.0246
BMI 27.01 4.56 30.09 6.62 0.0001
F Sex % 61.90% 59.20% 0.6703
Kellgren–Lawrence
x-ray grade
% With 0/1/2/3/
4
65/35/
0/0/0
0/0/38/
50/12
Numerical rating
scale (0-10)
0.43 1.06 4.74 3.08 0.0000000000021
Intermittent pain
intensity (0-5)
0.32 0.62 2.12 1.40 0.0000000000000062
Constant pain
intensity (0-5)
0.10 0.30 1.92 1.61 0.0000000000014
Years knee pain 0 6.74 9.11 N/A
Unilateral vs
bilateral knee
pain (%)
N/A 52.3/
47.7%
Pressure pain
detection
thresholds (log10 in
y´kg/m/s2)
Tibialis anterior
index knee
2.60 0.23 2.51 0.27 0.0093
Lateral index
knee
2.82 0.21 2.69 0.29 0.0003
Medial index
knee
2.72 0.24 2.62 0.29 0.0045
Sternum 2.49 0.20 2.40 0.33 0.0135
Anxiety HADS
score (0-21)
5.65 3.90 7.73 4.56 0.0005
Moderate or high
anxiety (.10)%
10.0% 25.4% 0.0040
Depression
HADS score
(0-21)
3.34 2.82 5.72 3.76 0.0000026
Moderate/high
depression
(.10) %
4.0% 10.0% 0.0951
Medications (% prevalence) Mean Mean P
Use of analgesics 21.0% 41.5% 0.0012
Paracetamol 11.0% 15.4% 0.3354
NSAIDs (topical and oral) 12.0% 26.2% 0.0092
Opioids 5.0% 20.8% 0.0014
Antineuropathics* 0.0% 6.9% 0.3444
Other pain medication† 1.0% 2.3% 0.4556
SNRI‡ 1.0% 1.5% 0.7222
Antidepressants used to treat pain 4.0% 8.5% 0.1774
Patients with knee OA were on average 3 years older and 3 kg/m2 heavier than controls; therefore, all
analyses have been adjusted for these covariates. Because controls were all selected to be pain-free, all
questionnaire-based pain scores are significantly higher in knee OA cases than in controls, as is use of
analgesics. All pressure pain threshold measures are also significantly lower (reflecting higher pain
sensitivity) in cases than in controls, as are the anxiety and depression scores. Statistical significance was
assessed using t tests, and exact P values are stated. Values in bold reached statistical significance, whilst
those in italics did not.
* Gabapentin, pregabalin, duloxetine, capsaicin patch.
† Nefopam hydrochloride.
‡ Duloxetine, venlafaxine.
BMI, body mass index; NSAID, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; SNRI, serotonin-
noradrenaline reuptake inhibitor; StDev, standard deviation.
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microglial cells (Figs. 3E and F), but no significant difference
between strains. These data replicate our previous work
demonstrating MIA-induced activation of microglial cells in the
spinal cord,42 but suggest that elevated anxiety does not lead to
increased microglial activation in the spinal cord.
Because anxiety is mediated supraspinally, we also investi-
gated changes in astrocyte activation in pain-associated regions
of the brain. We observed a bilateral increase in GFAP
immunofluorescence in the ventrolateral PAG (Figs. 4A–C) and
ACC (Figs. 4E–G) inWKY-MIA rats, but not in SD-MIA rats (Figure
S3, available at http://links.lww.com/PAIN/A696; & Figs. 4C and
G). Lowered contralateral PWTs in MIA-treated WKY rats were
correlated with GFAP immunofluorescence in both the ventro-
lateral PAG (Spearman’s r 5 20.74, P 5 0.0079, Fig. 4D) and
ACC (Spearman’s r 5 20.58, P 5 0.0496, Fig. 4H).
To consolidate the link between altered PWTs and increased
GFAP immunofluorescence, an intervention study was per-
formed. Duloxetine (30 mg/kg, subcutaneous) reversed
Figure 1. Association between anxiety status (low5HADS score#10; high5HADS score.10) and pain measures in patients with knee OA (n5 130) vs healthy
controls (n5 100). Association between anxiety status and self-reported pain (A) in patients with knee OA, and pressure pain detection thresholds (PPTs) at the
anterior tibia (B), and the lateral (C) and medial (D) aspects of the index knee, and at the sternum (E) in knee OA vs healthy controls. Data are mean log10 PPT6
SEM. P-values are derived from linear regression where pain scores or PPTs are the outcome and anxiety status (low or high) is the predictor variable, adjusting for
age, sex, BMI, and depression status as per the analysis in Table 1. †P , 0.10, *P , 0.05, **P , 0.01, ***P , 0.0001. BMI, body mass index; HADS, Hospital
Anxiety and Depression Scale; ICOAP, Intermittent and Constant Osteoarthritis Pain scale; OA, osteoarthritis.
Table 2
Association between pressure pain thresholds (PPTs), self-reported pain scores, anxiety, and depression status in knee OA
cases and controls.
Anxiety status Depression status
Beta 95% CI P Beta 95% CI P
Knee OA
NRS 1.308 (0.315 to 1.926) 0.011* 1.759 (0.283 to 2.313) 0.0211*
Constant pain intensity 0.965 (0.400 to 1.749) 0.0011† 0.258 (20.663 to 21.042) 0.5845
Intermittent pain intensity 1.301 (0.682 to 2.637) 0.0001‡ 0.17 (20.039 to 0.093) 0.1146
Anterior tibia PPT 20.162 (20.270 to 20.691) 0.0038† 0.053 (20.107 to 20.158) 0.5203
Knee lateral PPT 20.12 (20.240 to 20.590) 0.0524 ns 20.039 (20.217 to 20.463) 0.6726
Knee medial PPT 20.166 (20.276 to 20.707) 0.0037† 0.054 (20.110 to 20.161) 0.5189
Sternum PPT 20.4 (20.706 to 21.783) 0.0115* 0.058 (20.396 to 20.718) 0.8013
Controls
Anterior tibia PPT 20.084 (20.234 to 20.542) 0.274 20.079 (20.318 to 20.702) 0.5206
Knee lateral PPT 20.083 (20.225 to 20.524) 0.2597 20.036 (20.264 to 20.554) 0.761
Knee medial PPT 20.072 (20.229 to 20.521) 0.3668 20.02 (20.270 to 20.550) 0.8772
Sternum PPT 20.152 (20.462 to 21.058) 0.3389 20.224 (20.721 to 21.637) 0.3785
NB: Anxiety status is reported after adjustment for depression, and vice versa. Raw PPT values can be found in Table 1. Depression and anxiety status are defined as absent/low if HADS score#10, or moderate/high if HADS
score .10 using established clinical cutoffs for this instrument. Given the absence of knee pain in controls, self-reported pain scales are not reported for this group. Italics indicate a lack of statistical significance.
* P , 0.05.
† P , 0.01.
‡ P , 0.0001.
CI, confidence interval; HADS, Hospital Anxiety and Depression Scale; NRS, numerical rating scale; OA, osteoarthritis.
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established reductions in ipsilateral and contralateral PWTs in
WKY-MIA rats (Table 4). This effect was associated with
significantly lower GFAP immunofluorescence in the dorsal horn
of the spinal cord and ventrolateral PAG of WKY-MIA rats. There
was no change in the level of GFAP immunofluorescence in the
ACC (Table 4). In SD-MIA rats, duloxetine reversed weight-
bearing asymmetry, but had no effect on the contralateral PWTs
(data not shown). Our data demonstrate increased basal, and
MIA-induced, astrocyte activation associated with an altered pain
phenotype in the WKY strain, and that both can be reversed by
a centrally acting anxiolytic.
4. Discussion
In this study, we show that higher anxiety scores, but not depression
scores, are significantly associated with higher pain sensitivity in
individuals with knee OA. In addition, after adjusting for the effect of
depression, anxiety score at baselinewas associatedwith increased
risk of knee pain at 12 months. Anxiety at baseline was also
associatedwith augmented pain behaviour in a rodentmodel of OA.
In this model, we demonstrated increased activation of a marker of
astrocytes in the PAG and ACC in the high-anxiety OA model.
Pharmacological attenuation of existing OA behavioural pain
responses in thehigh-anxietymodelwasassociatedwith adecrease
in the glial cell response in the PAG, suggesting a role for astrocytes
in the link between anxiety and OA pain.
4.1. Osteoarthritis and anxiety associated with augmented
pain responses
The lowered PPTs at both the OA joint (knee) and remote sites
(sternum) in our study suggest altered central pain processing in
individuals with OA, consistent with previous reports.2,37 Herein,
we demonstrate that individuals with OA and high anxiety
reported greater pain and had lowered PPTs as assessed by
QST, compared to individuals with OA and normal anxiety levels.
Associations between anxiety and PPTs, and self-reported pain
in the knee OA cohort remained significant after adjustment for
depression. Our novel findings are consistent with previous data
showing correlated self-reported pain and anxiety scores and
increased disability in an outpatient population3 and community
population5 with OA and anxiety or depression.
To better understand the longer-term impact of anxiety on
knee pain, an analysis of a large number of individuals from the
general population was undertaken. This revealed that high
anxiety scores predicted the onset of knee pain over a 1-year
Figure 2. AugmentedMIA-inducedpain behaviour, but not knee pathology, in theWKY rat. (A) Intra-articular injection ofMIA produced similar alterations inweight-bearing
asymmetry in SD andWKY rats, compared with their respective saline-treated controls. However, a significantly greater decrease in ipsilateral and contralateral hind paw
withdrawal thresholds (PWTs) was observed inWKY-MIA rats, demonstrating augmented pain behaviour in this strain. Data aremean6SEM, 2-way analysis of variance
with Bonferroni post hoc testing. *P, 0.05, **P, 0.01 ***P, 0.001 vs saline; #P, 0.05, ##P, 0.01 vs SD-MIA. (B) EnhancedMIA-induced pain behaviour in theWKY
strain was not accompanied by altered joint pathology, with similar cartilage damage and joint inflammation scores compared to SD-MIA rats (n5 8). Data are medians,
Kruskal–Wallis test with Dunn post hoc testing *P, 0.05. MIA, monosodium iodoacetate; SD, Sprague-Dawley.
Table 3
Association between anxiety, OA status, and pain behaviour in
the preclinical WKY-MIA model of OA.
Comparison Anxiety
Beta 95% CI P
OA model 0.873 (0.205-3.71) 0.85
Increase in anxiety 4.63 (0.92-23.3) 0.063
Ipsilateral PWT 1.69 (0.41-6.88) 0.46
Contralateral PWT 44.0 (4.31-448.6) 0.0014*
Linear regression analyses were performed using data from WKY and Wistar rats. Anxiety status was defined
as having an AUC for time spent in open arms less than the mean value for all animals in the elevated plus
maze at that time point. Anxiety was predictive of contralateral, but not ipsilateral pain at D21, suggesting that
elevated anxiety is associated with a widespread pain phenotype in this model, as in the human data. The OA
model (MIA administration) was not associated with the incidence of anxiety. Anxiety at baseline showed
a trend towards association with increased anxiety at D21, but did not reach significance *p , 0.05.
CI, confidence interval; OA, osteoarthritis; MIA, monosodium iodoacetate; PWT, paw withdrawal threshold.
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Figure 3. EnhancedMIA-induced pain behaviour in theWKY rat is accompanied by activation of spinal astrocytes, but not microglial cells. Representative images
of astrocyte activation visualised throughGFAP immunofluorescence in the ipsilateral spinal cord dorsal horn in theWKY strain 21 days after intra-articular injection
of saline (A) or MIA (B). Quantification revealedMIA-induced astrocyte activation in the ipsilateral spinal cord of both SD andWKY rats when compared with saline-
treated controls (C), but changes in GFAP expression weremore pronounced inWKY rats, and spinal GFAP expression levels were significantly higher bilaterally in
both saline and MIA-treated WKY rats compared with their SD counterparts. GFAP expression (defined as GFAP1 area) was significantly correlated with
decreased contralateral PWTs in the WKY strain (D), suggesting a clear association between astrocyte activation and augmented pain behaviour. GFAP1 area
was calculated as the number of pixels with intensity.55 in each area. Scale bars5 50mm.Data aremean6SEM. ***P, 0.001, ****P, 0.0001 vs saline control,
#P, 0.05, ####P, 0.0001 vs SD-MIA, ^^^^P, 0.0001 WKY-MIA vs SD-MIA. By contrast, no strain differences were observed in spinal microglial activation
assessed through P-p38 expression (E and F) or morphological analyses (G). Representative spinal cord image demonstrating P-p38 (red) expressed almost
exclusively in IBA-1–positive (green) activated microglial cells (E). Quantification revealed a similar bilateral activation in P-p38–expressing spinal microglial cells
after MIA injection in both SD andWKY rat strains (F). Morphological analysis also revealed a similar MIA-induced increase in ipsilateral microglial activation in both
strains (G). Data are mean6 SEM, analysed using 1-way (microglia) or 2-way (P-p38) analysis of variance with Bonferroni post hoc testing. *P, 0.05, **P, 0.01,
***P, 0.001 vs respective saline-treated controls. (n5 5 rats per group, 6-7 sections per rat). GFAP, glial fibrillary acidic protein; MIA, monosodium iodoacetate;
PWT, paw withdrawal threshold; SD, Sprague-Dawley.
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period, but knee pain at baseline did not statistically alter the
onset of high anxiety. A recent study reported that moderate to
very severe pain was associated with a higher risk of mood or
anxiety disorders at 3 years,13 indicating the importance of early
and successful treatment interventions for people with OA knee
pain. Taken together, our findings support the hypothesis that
anxiety drives an increase in sensory pain thresholds both at the
site of disease and remote sites, and an individual’s self-reporting
Figure 4.Monosodium iodoacetate–induced pain behaviour in the WKY rat is accompanied by activation of supraspinal astrocytes not seen in normo-anxiety SD
rats. Representative images demonstrate increased GFAP immunofluorescence in the right PAG (B) and ACC (F) in the WKY strain compared with saline-treated
controls (A and E, n5 5/group). Quantification revealed MIA-induced astrocyte activation bilaterally in the PAG (C), and unilaterally in the ACC (G), of WKY, but not
SD rats (see Figure S3, available at http://links.lww.com/PAIN/A696). GFAP expression (defined as GFAP1 area) in the right PAG and right ACC correlated with
contralateral PWTs in the WKY strain (D and H), suggesting a clear association between supraspinal astrocyte activation and augmented pain behaviour in the
WKY strain. GFAP1 area was calculated as the number of pixels with intensity.55 in each area. Scale bars5 50mm. Data are mean6 SEM. **P, 0.01, ****P,
0.0001 vs saline control, ##P , 0.01, ####P , 0.0001 vs SD-MIA. ACC, anterior cingulate cortex; GFAP, glial fibrillary acidic protein; MIA, monosodium
iodoacetate; PAG, periaqueductal gray; PWT, paw withdrawal threshold; SD, Sprague-Dawley.
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of pain. Our findings have wide-ranging implications for the
treatment of comorbid pain and anxiety, andmay account for why
individuals with high anxiety and OA have a reported higher level
of opioid use.5,38
4.2. Anxiety is associated with spread of pain to remote sites
in the WKY-MIA model of anxiety and osteoarthritis pain
Before induction of themodel ofOA,WKY rats exhibited a heightened
behavioural anxiety–like profile, as expected.18,34 In our study,
behavioural scores of anxiety at baseline were a predictor of pain
behaviourafter inductionof theMIAmodelofOA, validating theutility of
the WKY strain of rat to investigate the mechanisms mediating the
influence of anxiety on OA pain. The measure of mechanical
hypersensitivity (reduced ipsilateral PWTs43) was greater in WKY-
MIA than in SD-MIA. WKY-MIA rats also had lowered PWTs in the
contralateral hind paw, replicating the remote pain reported clinically in
OA2 and in our clinical study of individuals with OA and high anxiety
levels. By contrast, the surrogate behavioural test of pain on loading
(weight-bearing) was comparable between the 2 strains in the model
of OA pain. This likely reflects the influence of bilateral lowering of
PWTs in theWKY rats, which confounds tests dependent on a shift in
weight bearing from the injured to the uninjured side.
Given the established role of astrocytes in preclinical models of
musculoskeletal pain,42,49 and in the transition from acute to
chronic pain states,18,24 the potential role of these glial cells was
investigated. In themodel of OApain, GFAP immunofluorescence
was significantly increased in the ipsilateral spinal dorsal horn in
both strains of rats, but to a significantly greater extent in theWKY
rats. Although spinal cord microglia have an established role in
sensitization of pain processing36 and are activated in this model
of OA pain,42 we found no differences in the numbers of activated
microglia in the ipsilateral spinal cord between the SD-MIA and
WKY-MIA rats. These data suggest that, at this time point at least,
astrocytes in the spinal cord play a more prominent role in
heightened OA pain responses associated with anxiety.
Within the brain, there was a significant bilateral increase in
GFAP immunofluorescence in the ventrolateral PAG and a unilat-
eral increase in the right ACC inWKY-MIA rats, but not in SD-MIA
rats. The ACC has been identified as a key structure in
anxiety–chronic pain interactions, mediating both pain-driven
increases in anxiety and subsequently enhanced pain, through
distinct mechanisms.61 As glial activation is associated with
increased neural activity, and differences in astrocytes in specific
brain regions were correlated with the pain behaviour specific to
WKY-MIA rats (contralateral lowering of PWTs), these data
suggest astrocytes in the ACC and PAG are potential drivers of
the CNS mechanisms by which anxiety contributes to pain
phenotype in this OAmodel. Indeed, recent studies have pointed
to a key role for astrocyte activation in the generation of
contralateral pain phenotypes in mouse models of neuropathic
pain,22,28 unmasked by a shift in the balance between excitation
and inhibition. A mechanism such as this may be of particular
relevance to the spread of OA pain to remote sites, which is likely
a centrally mediated phenomenon.
Tobetter understand thepotential associations andmechanisms,
we undertook a pharmacological study with duloxetine, which acts
centrally to increase synaptic levels of serotonin (5-HT) and
noradrenaline (NA) in numerous brain regions15,26 and has analgesic
effects in chronic pain states.31,40 Duloxetine reversed both the
contralateral pain phenotype specific to WKY-MIA rats and the
increased bilateral GFAP immunofluorescence in the ventrolateral
PAG, but had no effect on GFAP in the right ACC of WKY-MIA rats.
These data suggest that the effects of duloxetine on anxiety-driven
OA pain are occurring at the level of the brainstem, which would be
consistent with the known role of this region in driving the
descending inhibitory control pathways.39 Although numerous
studies have demonstrated short-term effects of duloxetine on
astrocytes in the spinal cord inmodels of pain,10,30,44 our study is the
first to report of an effect of duloxetine on astrocytes in a pain-
associated brain region. Our findings support a role of central
mechanisms driving facilitated OA pain responses under conditions
of high anxiety, and consolidate the link between astrocyte activation
in discrete brain regions and contralateral pain behaviour.
4.3. Study limitations
We note several limitations with this study that are worth
considering when evaluating the results. In our clinical data, we
did not assess the role of anxiety on pain thresholds in pain-free
individuals with radiographic OA; hence, we cannot draw
conclusions regarding nonpainful radiographic OA. However,
although the effects of anxiety on PPTs were not significant in
control individuals, this could be due to the smaller number of
high-anxiety, knee pain-free participants included in this study.
For some sites, effects of anxiety on PPTs were considerably
larger in knee OA participants than in controls (eg, medial PPTs
knee OA participants 5 0.59 StDev, control participants 5 0.37
StDev). However, anxiety-induced differences in sternum PPTs
were virtually identical in knee OA cases (0.48 StDev), and
controls (0.47 StDev), and the lack of statistical significance in the
latter group here can be accounted for by a lack of power. Finally,
we assessed all PPTs over bone, and findings may not be
generalizable to the wider musculoskeletal field where PPTs are
sometimes assessed over muscle.17
There are also some limitations to the preclinical work. Male
rats only were used for this study to reduce intragroup variability
while developing the model and to maintain consistency with our
Table 4
Duloxetine reverses anxiety-like behaviour and reduces MIA-
induced pain behaviour and astrocyte activation in a ratmodel
of high anxiety.
WKY-saline WKY-
MIA-vehicle
WKY-MIA-duloxetine
Open field (% time in
central zone)
18 6 2 34 6 5†
Ipsilateral PWT (g)
D0 13 6 3 16 6 7 16 6 4
D14 14 6 6 7 6 2* 7 6 1*
D22 13 6 3 4 6 2† 13 6 5§
Contralateral PWT (g)
D0 17 6 6 17 6 8 17 6 5
D14 16 6 5 9 6 3* 8 6 3†
D22 18 6 7 7 6 2† 15 6 7§
GFAP1 pixels (31000)
S. Cord 17 6 4 26 6 3† 20 6 3‡
Periaqueductal gray 20 6 4 29 6 2† 23 6 3
Anterior cingulate
cortex
2 6 1 5 6 1* 5 6 1*
Pain and anxiety-like behaviour (open-field test) and activation of astrocytes in the spinal cord and
periaqueductal gray were reversed by a 3-d treatment with duloxetine (30 mg/kg subcutaneous, n 5 10)
from D18 to 21 after MIA administration. Astrocyte activation in the anterior cingulate cortex was unaffected
by duloxetine. Data are mean 6 SEM.
* P , 0.05.
† P , 0.01 vs WKY-saline.
‡ P , 0.05.
§ P , 0.01 vs WKY-MIA-vehicle.
GFAP, glial fibrillary acidic protein; MIA, monosodium iodoacetate; PWT, paw withdrawal threshold.
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previous work.43 However, this reduces the translational value of
the data because;60% of our clinical subjects were female, OA
is more prevalent in the female population, and females tend to
have more severe knee OA.48 It will be important to determine
whether there are any sex-specific effects in this model of anxiety
and OA-like pain in future studies.
5. Conclusion
Pain pressure thresholds and anxiety scores in people with knee
OA are highly associated, and anxiety at baseline predicts future
knee OA 1 year later. Our clinical data support the investigation
of new targets for treating pain in high-anxiety patients with OA.
We have successfully developed a rodent model of comorbid
anxiety andOA, in which anxiety at baseline was associatedwith
greater pain behaviour and an increase in activation of
astrocytes in the PAG and ACC brain regions in the model of
OA. The sensitivity of both pain responses and glial cell
activation in the PAG to pharmacological intervention in this
model suggests a potential role of the astrocytes in the link
between anxiety and OA pain.
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